Arcturus Therapeutics (NASDAQ:ARCT) Given “Overweight” Rating at Cantor Fitzgerald

Cantor Fitzgerald reaffirmed their overweight rating on shares of Arcturus Therapeutics (NASDAQ:ARCT) in a report published on Monday,Benzinga reports.

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $63.00 price objective on shares of Arcturus Therapeutics in a research report on Friday, November 8th. Six investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $66.75.

Arcturus Therapeutics Stock Performance

Arcturus Therapeutics stock opened at $16.24 on Monday. The stock has a market cap of $439.89 million, a PE ratio of -7.29 and a beta of 2.62. Arcturus Therapeutics has a fifty-two week low of $14.93 and a fifty-two week high of $45.00. The firm’s 50-day simple moving average is $18.91 and its 200 day simple moving average is $22.21.

Arcturus Therapeutics (NASDAQ:ARCT) last announced its quarterly earnings data on Thursday, November 7th. The biotechnology company reported ($0.26) EPS for the quarter, topping the consensus estimate of ($0.70) by $0.44. The business had revenue of $41.67 million for the quarter, compared to analyst estimates of $49.16 million. Arcturus Therapeutics had a negative net margin of 36.39% and a negative return on equity of 22.39%. During the same quarter in the previous year, the firm posted ($0.61) earnings per share. As a group, analysts predict that Arcturus Therapeutics will post -2.31 EPS for the current fiscal year.

Insider Activity

In related news, COO Pad Chivukula sold 12,000 shares of the business’s stock in a transaction that occurred on Tuesday, October 15th. The shares were sold at an average price of $20.76, for a total transaction of $249,120.00. Following the completion of the transaction, the chief operating officer now owns 435,334 shares of the company’s stock, valued at approximately $9,037,533.84. The trade was a 2.68 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 15.30% of the company’s stock.

Hedge Funds Weigh In On Arcturus Therapeutics

Several hedge funds have recently bought and sold shares of the company. Franklin Resources Inc. grew its stake in Arcturus Therapeutics by 54.6% during the third quarter. Franklin Resources Inc. now owns 103,936 shares of the biotechnology company’s stock valued at $2,412,000 after acquiring an additional 36,714 shares in the last quarter. Geode Capital Management LLC grew its stake in Arcturus Therapeutics by 1.1% in the 3rd quarter. Geode Capital Management LLC now owns 551,798 shares of the biotechnology company’s stock worth $12,810,000 after buying an additional 5,789 shares in the last quarter. XTX Topco Ltd grew its stake in Arcturus Therapeutics by 51.1% in the 3rd quarter. XTX Topco Ltd now owns 36,990 shares of the biotechnology company’s stock worth $859,000 after buying an additional 12,509 shares in the last quarter. PDT Partners LLC purchased a new position in Arcturus Therapeutics in the 3rd quarter worth approximately $1,744,000. Finally, Verition Fund Management LLC purchased a new position in Arcturus Therapeutics in the 3rd quarter worth approximately $420,000. Hedge funds and other institutional investors own 94.54% of the company’s stock.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.